olfactory receptor family 9 subfamily G member 3 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR9G3P profile across patient tissues and cancer cell-line models. OR9G3P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, OR9G3P is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, OR9G3P RNA expression shows 5,772 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, PRAD, and STAD as cancer lineages where OR9G3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR9G3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR9G3P survival associations across molecular data types. OR9G3P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR9G3P RNA expression–survival associations across cancer types. High OR9G3P expression shows unfavorable associations in THCA, READ, PCPG, BLCA and UCEC, but favorable associations in STAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for OR9G3P RNA expression.
This table summarizes OR9G3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR9G3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR9G3P shows lower tumor expression in PRAD. The PRAD box plot shows higher OR9G3P RNA expression in normal versus tumor tissue (log2 FC = −0.040, t-test p = .006).
This table shows molecular features associated with OR9G3P in patient tissues and cancer cell lines. In patient samples, OR9G3P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
